EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Amgen
- Study ID
- NCT05284747
- Phase
- PHASE4
- Status
- Active Not Recruiting
Conditions
- Cardiovascular Disease
- Coronary Revascularization
- Myocardial Infarction
- Stroke
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- Evolocumab — DRUGEvolocumab will be provided as a single-dose, prefilled autoinjector pen (AI/pen) for fixed dose subcutaneous (SC) injection.
- Routine Lipid Management — DRUGRoutine lipid management therapies will be administered at the discretion of the investigator per SoC.
Study Details
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction \[NSTEMI\] and ST-segment elevation myocardial infarction \[STEMI\]).
Key Dates
- Start date
- Oct 26, 2022
- Status verified
- Oct 2025
- Primary completion
- May 29, 2027
- Completion
- May 29, 2027
Study Design
- Enrollment
- 6,019 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Evolocumab + Routine Lipid ManagementParticipants will receive open-label evolocumab every 2 weeks (Q2W) plus routine lipid management.
- Active Comparator: Routine Lipid ManagementParticipants will receive routine lipid management per standard of care (SoC).
Primary Outcome Measure
Total (first and subsequent) composite of myocardial infarction, ischemic stroke, any arterial revascularization procedure, and all-cause death [ Time Frame: From Baseline to End of Study (Approximately 3.5 Years) ]
Locations (81)
Find similar trials in Birmingham, AL
By condition
By specialty
By research site
University of Alabama at Birmingham· Birmingham, ALEastern Shore Research Institute· Fairhope, ALHeart Center Research LLC· Huntsville, ALNorthern Arizona Healthcare Corporation Cardiovascular Institute· Flagstaff, AZScottsdale Healthcare at Shea - HonorHealth· Scottsdale, AZPima Heart and Vascular Clinical Research· Tucson, AZ
Related Studies
- Evaluation of an Advanced Lower Extremity NeuroprosthesesRecruiting · Case Western Reserve University · Cleveland, Ohio
- Genetic and Environmental Risk Factors for Hemorrhagic StrokeRecruiting · State University of New York at Buffalo · Chicago, Illinois
- Circulating Markers for Ischemic Heart DiseaseRecruiting · UConn Health · Farmington, Connecticut
- Identification of Genomic Predictors of Adverse Events After Cardiac SurgeryRecruiting · Brigham and Women's Hospital · Boston, Massachusetts